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A B S T R A C T
Background: This study examined the prevalence of hallucinogen use in a large sample of university students and
its associations with mental health issues.
Methods: 9449 students received a 156-item anonymous online survey, which assessed the use of hallucinogens
(ever or past year), alcohol and drug use, mental health issues, and impulsive and compulsive traits. Group
diﬀerences were characterized using statistical tests (p values reported uncorrected, but only regarded as sig-
niﬁcant if surviving Bonferroni correction).
Results: 3525 university students (57.7% female) responded to the survey. The prevalence of past 12-month
hallucinogen use in the sample was 4.7%, with an additional 6.4% reporting having used more than 12months
ago. Hallucinogen use was associated with the use of multiple other drugs (e.g., alcohol, opiates) (each
p < 0.001), mental health problems (p < 0.001), risky sexual behavior (p < 0.001), low self-esteem
(p=0.004), and impulsivity traits (p < 0.001) but not compulsivity. Eﬀect sizes were small to medium.
Conclusion: Past use of hallucinogens was reported in 11.1%, and was associated with a variety of mental health
and drug use problems. Clinicians should be aware that use of hallucinogens is common and mental health
problems are more likely in those who use hallucinogens. This study indicates the need for longitudinal research
into the negative eﬀects of hallucinogen use on brain function and mental health, especially in young people.
Such research should address the extent to which impulsive traits predispose to various substance use problems,
versus the direct eﬀects of hallucinogens (and other substances) on mental health.
1. Introduction
Plant-based hallucinogens have been used throughout the world for
thousands of years (Bruhn, de Smet, El-Seedi, & Beck, 2002). In recent
years, there is a renewed interest in several hallucinogens as novel
agents to treat psychiatric disorders – such as psilocybin for treatment
of substance use disorder or refractory depression (Bogenschutz et al.,
2015; Carhart-Harris et al., 2017); or MDMA for post-traumatic stress
disorder or social anxiety disorder (Danforth, Struble, Yazar-Klosinski,
& Grob, 2016; Sessa, 2017). While apparent positive beneﬁts of such
substances on aspects of mental health have been reported by some
researchers (Hendricks, Thorne, Clark, Coombs, & Johnson, 2015),
there is a long history of adverse reactions to many of these substances
reported in the psychiatric literature, e.g. (Horowitz, 1969;
Ungerleider, Fisher, Fuller, & Caldwell, 1968).
The term “Hallucinogen” in the Diagnostic and Statistical Manual
Version 5 (DSM-5) refers to a large category of psychedelic drugs that
produce similar alterations of perception, mood and cognition
(American Psychiatric Association, 2013). These substances include
psilocybin, mescaline and lysergic acid diethylamide (LSD), the NMDA
antagonist phencyclidine (PCP), 3,4-Methylenedioxy-methampheta-
mine (MDMA), and Salvia divinorum (American Psychiatric
Association, 2013). Recent data from the National Epidemiologic
Survey on Alcohol and Related Conditions (NESARC) (n= 36,255)
found that 12-month and lifetime prevalence rates for hallucinogen use
were 0.62% and 9.32%, respectively, with a mean age of onset of
hallucinogen use of 17 years (Shalit, Rehm, & Lev-Ran, 2019). Given
the long history of hallucinogen use throughout the world, and the data
showing that use is fairly common today, questions remain as to whe-
ther and to what extent these substances are problematic for many
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people (Carbonaro et al., 2016).
Use of hallucinogens frequently presents alongside other substance
use issues and mental health problems. Using the NESARC data, Shalit
and colleagues reported that hallucinogen use was signiﬁcantly asso-
ciated with mood disorders, anxiety disorders (particularly PTSD),
eating disorders, personality disorders, substance use disorders (parti-
cularly opiate use disorder), and past suicide attempts (Shalit et al.,
2019). These data however are inconsistent with other studies that have
failed to ﬁnd mental health associations with hallucinogen use or in fact
have found hallucinogen use to be potentially associated with lower
mental health problems (Hendricks et al., 2015; Krebs & Johansen,
2013).
In view of the recent renewed interest in these substances and the
inconsistent ﬁndings of mental health associations with hallucinogens,
the current study sought to examine both the prevalence of the use of
hallucinogens among university students; and to examine related be-
haviors and mental health issues. We included questionnaire-based
measures of impulsivity and compulsivity, since these concepts have
been implicated in diﬀerent stages of addiction (Yucel et al., 2018).
Based on the previous literature, we hypothesized that the use of hal-
lucinogens would be associated with elevated rates of other substance
use, mental health issues, trait impulsivity and compulsivity, riskier
sexual practices, and academic impairments compared to students who
do not use hallucinogens.
2. Material and methods
2.1. Survey design
Researchers at the Department of Psychiatry and Behavioral
Neuroscience at the University of Chicago and Boynton Health Services
at the University of Minnesota jointly developed the Health and
Addictive Behaviors Survey, an online survey examining the use of al-
cohol, drugs, and mental health issues, in university students. All study
procedures were conducted in accordance with the Declaration of
Helsinki and the University of Minnesota’s Institutional Review Board
approved the study.
2.2. Participants
10,000 undergraduate and graduate/professional students at a large
Midwestern university were chosen randomly using a computer-gen-
erated selection with email addresses and sent an online survey during
a three-week period in the Autumn of 2016. Of the 10,000 email in-
vitations, 9449 were successfully received by the recipients. Of the
9449 students who received the invitation to participate, 3525 (37.3%)
completed the survey, a response rate in keeping with other health
surveys (Baruch & Holtom, 2008; van Horn, Green, & Martinussen,
2009).
The survey ﬁrst presented students with information sheets about
the study (including informing them that all information was anon-
ymous and conﬁdential). Students then provided consent to take part or
opted out. Subsequent questions were only presented when informed
consent had been provided. Students were informed that after com-
pleting the survey email address would be entered in to a raﬄe wherein
10 students would be randomly chosen to receive prizes: 3 would win
tablet computers, 4 would win $250 gift certiﬁcates to an online re-
tailer, 2 would win $500 gift certiﬁcates, and there would be a single
winner of a $1000 gift certiﬁcate. To maintain anonymity, the email
addresses were not linked to questionnaire responses. Participants were
required to review all survey questions to be eligible for the prize
drawings, but they were not required to answer all questions given the
sensitive nature of some items.
2.3. Assessments
The survey consisted of 156 questions and took approximately
30min to complete. Hallucinogen use was assessed by asking partici-
pants if they had used hallucinogens (e.g., LSD, MDA, MDMA [Ecstasy],
Mushrooms, Peyote) in the past year or used ever in their lifetime.
Participants were grouped into “current” hallucinogen use if they re-
ported using any in the last 12months, those who used hallucinogens
previously, but not in last 12 months, were labeled as “past” halluci-
nogen use. Those who had never used hallucinogens comprised the
third category.
The following demographic measures were collected: gender, year
in college, and Grade Point Average (GPA). In addition to asking de-
mographic, clinical, and sexual health information, the survey used
measures of interest focusing on three domains: Drug and Alcohol Use;
Mental Health Problems; and Impulsivity/Compulsivity:
2.3.1. Drug and alcohol use
Participants were asked if they had ever used an illicit drug (binary);
and were asked about whether they had used the following in the past
12months (each a binary response): amphetamines, cocaine, heroin,
hallucinogens, marijuana or hashish, prescription opioid pain medica-
tion, or sedatives. In addition to use of drugs and alcohol, participants
were screened for possible problematic use by using the Alcohol Use
Disorders Identiﬁcation Test (AUDIT) (score of≥8 indicating potentially
harmful alcohol use (Saunders, Aasland, Babor, de la Fuente, & Grant,
1993); and the Drug Abuse Screening Test (DAST-10) (score of 3 in-
dicating a positive screen for a drug use disorder) (Skinner, 1982;
Yudko, Lozhkina, & Fouts, 2007).
Table 1
Demographics of university students based on use of hallucinogens.
Variable Students who currently use
Hallucinogens (n= 167)
Students who have used
Hallucinogens in the past
(n=227)
Students who have never used
Hallucinogens (n=3131)
Statistic Likelihood
Ratio
P-Value Eﬀect Size
Cramer’s V
Sex, female, n (%) 84 (51.5) 105 (48.6) 1848 (62.2) LR=22.116 df= 6 0.001* 0.058
Year in college, n (%)
• Undergraduate 147 (88.0) 122 (53.7) 2053 (65.6) LR=58.791 < 0.001* 0.086• Graduate 20 (12.0) 104 (45.8) 1059 (33.8) df= 4• Non-degree 0 (0.0) 1 (0.4) 19 (0.6)
Race/ethnicity,
Caucasian
137 (84.6) 178 (82.4) 2216 (74.6) LR=15.118 df= 2 0.001* 0.065
Full time student, n (%) 157 (94.0) 192 (84.6) 2898 (92.6) LR=16.172 df= 2 <0.001* 0.075
Grade Point Average, GPA
Less than 3.00 37 (22.2) 33 (14.5) 292 (9.4) LR=26.258 < 0.001* 0.096
3.00 or higher 130 (77.8) 194 (85.5) 2799 (90.6) df= 2
* p < 0.05, Bonferroni corrected.
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Table 2
Alcohol, tobacco, and illicit drug use in students based on use of hallucinogens.
Variable Students who currently use
Hallucinogens (n=167)
Students who have used
Hallucinogens in the past
(n=227)
Students who have never
used Hallucinogens
(n= 3131)
Statistic Likelihood
Ratio
P-Value Eﬀect Size
Cramer’s V
Age at ﬁrst use of cigarettes or nicotine
• Never used 21 (12.6) 34 (15.0) 2064 (65.9) LR=432.337 <0.001* 0.251• Less than 14 years 24 (14.4) 42 (18.5) 134 (4.3) df= 6• 15–17 years 67 (40.1) 85 (37.4) 395 (12.6)• 18 years or older 55 (32.9) 66 (29.1) 537 (17.2)
Frequency of e-cigarette use
• Never 38 (26.0) 84 (43.5) 653 (61.4) LR=100.250 <0.001* 0.198• Not within past year 31 (21.2) 58 (30.1) 210 (19.7) df= 8• Rarely 53 (36.3) 34 (17.6) 145 (13.6)• Occasionally 14 (9.6) 13 (6.7) 34 (3.2)• Daily 10 (6.8) 4 (2.1) 22 (2.1)
Frequency of alcohol consumption
• Never 6 (3.6) 11 (4.8) 646 (20.6) LR=180.58 <0.001* 0.158• Monthly or less 9 (5.4) 29 (12.8) 632 (20.2) df= 8• 2–4 times a month 59 (35.3) 73 (32.2) 1003 (32.1)• 2–3 times a week 61 (36.5) 74 (32.6) 668 (21.3)• 4+ times a week 32 (19.2) 40 (17.6) 180 (5.8)
AUDIT score≥ 8 (%) 100 (59.9) 106 (46.7) 662 (21.2) LR=165.551 df=2 <0.001* 0.233
DAST-10 score≥ 3 (%) 90 (53.9) 75 (33.0) 125 (4.0) LR=435.113 df=2 <0.001* 0.452
Non-prescription amphetamines
• Never 146 (87.4) 187 (83.5) 3108 (99.3) LR=209.593 <0.001* 0.266• In past, not within past
12months
4 (2.4) 32 (14.3) 9 (0.3) df= 8
• Rarely 10 (6.0) 4 (1.8) 8 (0.3)• Occasionally 4 (2.4) 0 (0.0) 3 (0.1)• Daily 3 (1.8) 1 (0.4) 1 (0.0)
Cocaine
• Never 86 (51.8) 104 (46.8) 3045 (97.6) LR=740.374 <0.001* 0.466• In past, not within past
12months
23 (13.9) 97 (43.7) 42 (1.3) df= 6
• Rarely 45 (27.1) 20 (9.0) 24 (0.8)• Occasionally 12 (7.2) 1 (0.5) 8 (0.3)• Daily 0 (0.0) 0 (0.0) 0 (0.0)
Opiates
• Never 151 (90.4) 198 (88.4) 3118 (99.7) LR=164.873 <0.001* 0.238• In past, not within past
12months
6 (3.6) 25 (11.2) 6 (0.2) df= 8
• Rarely 5 (3.0) 0 (0.0) 1 (0.0)• Occasionally 2 (1.2) 0 (0.0) 1 (0.0)• Daily 3 (1.8) 1 (0.4) 1 (0.0)
Inhalants
• Never 145 (56.8) 205 (91.9) 3111 (99.6) LR=142.933 <0.001* 0.207• In past, not within past
12months
15 (9.0) 17 (7.6) 7 (0.2) df= 6
• Rarely 7 (4.2) 1 (0.4) 2 (0.1)• Occasionally 0 (0.0) 0 (0.0) 3 (0.1)• Daily 0 (0.0) 0 (0.0) 0 (0.0)
Sedatives
• Never 113 (67.7) 161 (71.6) 3078 (98.4) LR=381.561 <0.001* 0.325• In past, not within past
12months
21 (12.6) 47 (20.9) 26 (0.8) df= 8
• Rarely 17 (10.2) 12 (5.3) 13 (0.4)• Occasionally 13 (7.8) 2 (0.9) 9 (0.3)• Daily 3 (1.8) 3 (1.3) 1 (0.0)
Marijuana
• Never 3 (1.8) 3 (1.3) 2151 (68.7) LR=965.118 <0.001* 0.410• In past, not within past
12months
7 (4.2) 76 (33.6) 299 (9.6) df= 8
• Rarely 24 (14.4) 59 (26.1) 388 (12.4)• Occasionally 76 (45.5) 60 (26.5) 249 (8.0)• Daily 57 (34.1) 28 (12.4) 43 (1.7)
Prescription pain medication
• Never 103 (62.0) 120 (53.6) 3030 (96.9) LR=507.424 <0.001* 0.366• In past, not within past
12months
30 (18.1) 87 (38.8) 69 (2.2) df= 8
• Rarely 26 (15.7) 13 (5.8) 21 (0.7)• Occasionally 4 (2.4) 3 (1.3) 5 (0.2)
(continued on next page)
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2.3.2. Mental health problems
Participants were screened with the following reliable and valid
measures; Patient Health Questionnaire (PHQ-9) (score of ≥10 in-
dicating depressive symptoms of moderate or higher severity)
(Kroenke, Spitzer, & Williams, 2001); Generalized Anxiety Disorder 7
(GAD-7) (score of 10 or greater indicating clinically signiﬁcant anxiety)
(Spitzer, Kroenke, Williams, & Lowe, 2006); Primary Care PTSD Screen
(PC-PTSD) (score of≥ 3 indicating probable posttraumatic stress dis-
order, PTSD) (Prins et al., 2003); Adult ADHD Self-Report Scale (ASRS-
v1.1) Part A (6 questions screening for attention-deﬁcit/hyperactivity
disorder) (Kessler et al., 2005, 2007); Minnesota Impulsive Disorders In-
terview (MIDI) (screens for binge eating disorder and gambling dis-
order) (Chamberlain & Grant, 2018b; Grant, 2008); and the Rosenberg
Self-Esteem Scale (RSES) (score< 15 indicating low self-esteem)
(Rosenberg, 1965).
2.3.3. Impulsivity/compulsivity
Impulsivity refers to a tendency towards inappropriate, premature,
unduly hasty acts (Evenden, 1999); whereas compulsivity refers to a
tendency towards repetitive habitual actions (Chamberlain, Stochl,
Redden, & Grant, 2018). Barratt Impulsiveness Scale, Version 11 (BIS-11)
(three dimensions of impulsivity - attentional, motor, and non-plan-
ning) (Patton, Stanford, & Barratt, 1995; Stanford et al., 2016); and the
Cambridge-Chicago Compulsivity Trait Scale (CHI-T) (compulsive traits)
(Chamberlain & Grant, 2018a).
2.4. Data analysis
Participants were grouped a priori into current, past or non‐users
per the deﬁnitions provided above under ‘participants’. Categorical
variables were assessed using Pearson’s chi‐square tests. Continuous
variables were assessed using Analysis of Variance tests (ANOVA).
Eﬀect size was determined using Cramer’s V or Cohen’s D as appro-
priate. Our primary aim was to show how the groups actually
presented, rather than to statistically control for potential covariates, as
the former approach is intuitive to clinicians and more likely to be
relevant practically both to individuals who use hallucinogens and to
healthcare professionals seeing such people. SPSS was used for all sta-
tistical analyses (version 24; IBM Corp). Raw p values were reported but
ﬁndings were only deemed statistically signiﬁcant if they withstood
Bonferroni correction at p < 0.05 two-tailed for the number of mea-
sures within a given category of interest (i.e. per table of results).
Missing data were missing completely at random (MCAR) and the
analysis was conducted using listwise deletion. By far the most common
approach to the missing data is to simply omit those cases with the
missing data and analyze the remaining data. This approach is known
as the complete case (or available case) analysis or listwise deletion.
Listwise deletion is the most frequently used method in handling
missing data. Although this may introduce bias in the estimation of the
parameters, if the assumption of MCAR is satisﬁed, a listwise deletion is
known to produce unbiased estimates and conservative results. Also,
because this was a large sample, where power was not an issue, the
assumption of MCAR was satisﬁed and listwise deletion was thus ap-
propriate.
3. Results
Of the 3525 university students (57.7% female) the overall pre-
valence of past 12-month hallucinogen use was 4.7%, while an addi-
tional 6.4% reported lifetime use but not in the past year. Demographic
characteristics of the groups are presented in Table 1. It can be seen that
those who reported use (ever use/past year use) of hallucinogens were
more likely to be Caucasian and had signiﬁcantly lower educational
achievement scores (i.e. lower GPAs).
Hallucinogen use was signiﬁcantly associated with higher levels of
problematic alcohol and illicit substance use (AUDIT and DAST-10). In
addition, hallucinogen use was signiﬁcantly associated with a greater
likelihood of using numerous substances, in fact every category of
Table 2 (continued)
Variable Students who currently use
Hallucinogens (n=167)
Students who have used
Hallucinogens in the past
(n=227)
Students who have never
used Hallucinogens
(n= 3131)
Statistic Likelihood
Ratio
P-Value Eﬀect Size
Cramer’s V
• Daily 3 (1.8) 1 (0.4) 1 (0.0)
Data refer to N (percentage).
* p < 0.05, Bonferroni corrected.
Table 3
Sexual behavior in university students based on use of hallucinogens.
Variable Students who currently use
Hallucinogens (n= 167)
Students who have used
Hallucinogens in the past
(n= 227)
Students who have never used
Hallucinogens (n= 3131)
Statistic Likelihood
Ratio
P-Value Eﬀect Size
Cramer’s V
Has been sexually active
• Yes 151 (90.4) 214 (95.1) 2185 (70.5) LR=117.072 <0.001* 0.162• No 16 (9.6) 11 (4.9) 916 (29.5) df= 2
Age at ﬁrst sexual activity with another
• <11 years 2 (1.3) 2 (0.9) 17 (0.8) LR=85.636 <0.001* 0.128• 12–14 years 17 (11.3) 30 (14.0) 110 (5.0) df= 8• 15–17 years 77 (51.0) 116 (54.2) 867 (39.8)• 18–20 years 49 (32.5) 59 (27.6) 880 (40.4)• 21 years or older 6 (4.0) 7 (3.3) 306 (14.0)
Frequency of physical barrier use
• <50% of the
time
67 (44.4) 102 (47.7) 814 (37.4) LR=34.062 <0.001* 0.080
• 50–75% of the time 20 (13.2) 25 (11.7) 187 (8.6) df= 6• 76–95% of the time 26 (17.2) 41 (19.2) 352 (16.2)• 96–100% of the time 38 (25.2) 46 (21.5) 824 (37.9)
Data refer to N (percentage).
* p < 0.05 Bonferroni corrected.
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substance for which they were screened (see Table 2).
Table 3 presents the sexual behavior of participants. Hallucinogen
use was signiﬁcantly associated with being sexually active at a younger
age and engaging in sex more frequently, and without barrier contra-
ception.
Results from speciﬁc mental health screens are presented in Table 4.
Hallucinogen use was signiﬁcantly associated with higher rates of de-
pression, PTSD, ADHD, and anxiety. In addition, those who used hal-
lucinogens were more likely to report poorer self-esteem. Hallucinogen
use was not signiﬁcantly associated with gambling disorder, binge-
eating disorder, or higher caﬀeine use.
In terms of psychological traits, those who used hallucinogens re-
ported signiﬁcantly greater scores of impulsivity on all subscales of the
BIS-11, but did not report greater levels of compulsive traits on the CHI-
T (see Table 5).
4. Discussion
This study examined the prevalence of hallucinogen use in a large
sample of university students; and ways in which hallucinogen use was
related to concomitant use of other drugs as well as mental health and
academic achievement. We found that 4.7% of the sample reported past
12-month hallucinogen use (with an additional 6.4% having ever used
them). Overall, the lifetime rates found in our study (almost 11.1%) are
similar to (although somewhat higher than) those reported in the
NESARC study, where 9.32% had used hallucinogens in their lifetimes
(Shalit et al., 2019). Based on this study, hallucinogen use appears to be
particularly high in young adults, and these ﬁndings are concerning
regarding the long term eﬀects of this use during young adulthood.
Although research conducted in adolescents aged 12–17 years
(N= 55,286) suggests that the majority of young people who use hal-
lucinogens do not develop a hallucinogen use disorder, data did suggest
that approximately 30% of past-year hallucinogen users reported
symptoms of a hallucinogen use disorder and that 17% of hallucinogen
users met criteria for a past-year hallucinogen use disorder (Wu,
Ringwalt, Weiss, & Blazer, 2009). Which of these young adults will have
future problems with a hallucinogen use disorder is not, however,
known to be predictable on the individual level.
Clearly, young adults who use hallucinogens also use and have
problems with a range of addictive substances and unhealthy behaviors.
One possible explanation is that a common cognitive/personality fea-
ture underlies all of these problems associated with hallucinogen use
(for example, elevated impulsivity as seen on the BIS-11). Alternatively,
the use of various drugs may result in neurobiological changes that
predispose a young person to becoming impulsive. There are limited
data regarding adverse neurobiological eﬀects of hallucinogens based
on amount of drug used, frequency of use, and age of initiation of use. If
either of the above is true, at least for some young adults, then ad-
dressing the underlying impulsivity would be potentially more bene-
ﬁcial than directly addressing each problematic behavior.
Another, non-mutually exclusive explanation for the association of
hallucinogen use with using a variety of drugs and with impulsive be-
haviors and tendencies could be that various mental health problems
(e.g., depression, PTSD, etc.) give rise to young adults attempting to
self-medicate their emotional states with a variety of drugs, including
hallucinogens. This theory has led many to examine whether
Table 4
Impulsive behaviors and psychiatric history of university students based on use of hallucinogens.
Variable Students who currently use
Hallucinogens (n= 167)
Students who have used
Hallucinogens in the past
(n= 227)
Students who have never
used Hallucinogens
(n=3131)
Statistic Likelihood
Ratio
P-Value Eﬀect Size
Cramer’s V
Amount of caﬀeinated soft drinks consumed over the past week n (%)
• Never 83 (50.0) 97 (43.7) 1485 (48.3) LR=15.822 0.105 0.050• 1–2 drinks 47 (28.3) 84 (37.8) 988 (32.1) df= 10• 3–6 drinks 22 (13.3) 19 (8.6) 401 (13.0)• 7–12 drinks 7 (4.2) 11 (5.0) 138 (4.5)• 13–23 drinks 4 (2.4) 7 (3.2) 45 (1.5)• 24 or more drinks 3 (1.8) 4 (1.8) 20 (0.6)
Gambling disorder?
• Positive screen
4 (16.7) 0 (0.0) 10 (4.0) LR=7.276
df= 2
0.026 0.175
Binge eating disorder?
• Positive screen
2 (1.2) 9 (4.1) 72 (2.4) LR=3.390
df= 2
0.184 0.032
Has been treated for drug/
alcohol use problems
• Yes
12 (7.3) 18 (8.1) 32 (1.0) LR=54.789
df= 2
<0.001* 0.180
Has been treated for
psychological/emotional
problems
• Yes
75 (45.5) 101 (45.7) 851 (27.8) LR=48.405
df= 2
<0.001* 0.123
Currently taking prescribed
mental health medication(s)
• Yes
35 (21.2) 49 (22.2) 392 (12.8) LR=20.586
df= 2
<0.001* 0.082
PHQ-9 Total
• Score of 10 or more
42 (26.1) 44 (20.0) 405 (13.4) LR=22.654
df= 2
<0.001* 0.087
PTSD
• Positive screen
42 (26.1) 44 (20.0) 405 (13.4) LR=22.654
df= 2
<0.001* 0.087
Anxiety total Grouped
• No Anxiety (score 0–4) 70 (43.5) 107 (49.5) 1772 (59.6) LR=25.428 < 0.001* 0.062• Mild (score 5–9) 55 (34.2) 68 (31.5) 686 (23.1) df= 6• Moderate (score 10–14) 24 (14.9) 23 (10.6) 325 (10.9)• Severe (score 15–21) 12 (7.5) 18 (8.3) 192 (6.5)
ADHD
• Positive screen
48 (29.4) 60 (27.6) 482 (16.1) LR=31.573
df= 2
<0.001* 0.103
Rosenberg Self-esteem scale
• Less than 15
39 (24.4) 28 (13.1) 425 (14.4) LR=10.892
df= 2
0.004* 0.061
Data refer to N (percentage).
* p < 0.05 Bonferroni corrected.
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hallucinogens may oﬀer a rapid treatment for depression and other
mental health problems (Bogenschutz et al., 2015; Carhart-Harris et al.,
2017; de Gregorio, Enns, Nunez, Posa, & Gobbi, 2018).
Interestingly, we found that participants who used hallucinogens
reported worse depressive and anxiety symptoms, than those who had
never used hallucinogens, with no diﬀerences between current or past
users. Thus, these data fail to produce compelling evidence that hal-
lucinogens may be working as antidepressants or anxiolytics in this
ecological setting.
This study into the use of hallucinogens has the advantage of being
relatively large. Nonetheless, there are several limitations that should
be considered. The study was cross-sectional and hence the direction of
causality of any eﬀects cannot be established – this would require
longitudinal research on the topic; however, we hope that such cross-
sectional data will support such follow-up. There are also limitations
inherent in the study being conducted using an online interface via the
Internet – diagnostic assessment may be less accurate via such an online
survey compared to in-person assessment by a clinician; there may be
responder biases; and there may be under-reporting (though this pos-
sibility is reduced by individuals’ responses not being lacked to per-
sonally identiﬁable information). Additionally, self-report questions
pertaining to substance use and other potentially socially embarrassing
behaviors e.g. multiple sexual partners have their own limitations: for
example, individuals may not disclose the full extent of their actions or
may not report it accurately due to bias.
In summary, we found in a large sample of university students that
hallucinogens use was common, and associated with drug use and a
number of mental health problems, plus higher impulsivity.
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